There is evidence to suggest that, as in the NST, CCK and estradiol also act synergistically in the limbic-hypothalamic circuit
Since obesity, insulin resistance, liver fat, and metabolic dysfunction are closely linked, GLP-1 and glucagon-based combinations are being studied for their potential to reduce liver fat, improve metabolic markers, and slow disease progression
Monitoring parameters should include standard assessments: hemoglobin A1c and fasting glucose for diabetes management, body weight, blood pressure, and lipid profiles
Clinical trials that led to regulatory approval did not identify back pain as occurring at significantly higher rates in treatment groups compared to placebo
This may lead to: Tachycardia (abnormally fast heart rate) Significant spikes in blood pressure Heart palpitations or chest pain Increased anxiety or jitteriness Overlapping Side Effects Both medications come with their own list of side effects, and taking them together can make these symptoms more frequent or more severe